Erythropoetin (EPO) antibody and antigen (hapten, BSA/OVA conjugated)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-SMT-EPO-Ag01	BSA-Erythropoetin (EPO)	756
GMP-SMT-EPO-Ag02	OVA-Erythropoetin (EPO)	756
GMP-SMT-EPO-Ab01	Anti-human Erythropoetin (EPO) mouse monoclonal antibody (mAb)	1953
GMP-SMT-EPO-Ab02	Anti-human Erythropoetin (EPO) human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-SMT-EPO-Ag01
Product Name	BSA-Erythropoetin (EPO)
Target/Biomarker	Erythropoetin (EPO)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-EPO-Ag02
Product Name	OVA-Erythropoetin (EPO)
Target/Biomarker	Erythropoetin (EPO)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-EPO-Ab01
Product Name	Anti-human Erythropoetin (EPO) mouse monoclonal antibody (mAb)
Target/Biomarker	Erythropoetin (EPO)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-EPO-Ab02
Product Name	Anti-human Erythropoetin (EPO) human monoclonal antibody (mAb)
Target/Biomarker	Erythropoetin (EPO)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

Erythropoietin (EPO) is produced and released into the blood by the kidneys in response to low blood oxygen levels (hypoxemia). The amount of erythropoietin released depends on how low the oxygen level is and the ability of the kidneys to produce erythropoietin. EPO is carried to the bone marrow, where it stimulates production of red blood cells. The hormone is active for a short period of time and then eliminated from the body in the urine. However, if kidneys are damaged and do not produce enough erythropoietin, then too few RBCs are produced and leads to anemic. Similarly, if bone marrow is unable to respond to the stimulation from EPO also become anemic. This can occur with some bone marrow disorders or with chronic diseases, such as rheumatoid arthritis. The erythropoietin production increased with some benign or malignant kidney tumors and with a variety of other cancers, it also produces too many RBCs  (polycythemia or erythrocytosis). This can lead to an increase in the blood’s thickness (viscosity) and sometimes to high blood pressure (hypertension), blood clots (thrombosis), heart attack, or stroke. Rarely, polycythemia is caused by a bone marrow disorder called polycythemia vera, not by increased erythropoietin.

About GDU